The phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant. Kidney graft function stabilized after the first month of treatment and remained higher in tegoprubart-treated patients than in tacrolimus-treated patients at each reported time point, with a statistically significant kidney function benefit at 18 months. A recent analysis of BESTOW data found that tegoprubart also caused greater improvements in patient-reported health-related quality of life compared with tacrolimus in study participants. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
Tegoprubart Outperforms Tacrolimus in Kidney Transplant Patients, Study Shows
The phase 2 BESTOW clinical trial indicates that tegoprubart, a novel anti-CD40L antibody therapy, outperforms tacrolimus in preserving kidney function for first-time transplant patients. This finding is significant for improving patient outcomes in kidney transplantation. While the article does not directly relate to Iran, advancements in medical treatments could impact healthcare discussions in the country.
👥 Key Players
📰 What Happened
The phase 2 BESTOW clinical trial demonstrated that tegoprubart is more effective than tacrolimus in preserving kidney function in first-time kidney transplant patients. The results showed significant improvements in kidney function and patient-reported quality of life over 18 months.
- Tegoprubart showed statistically significant benefits in kidney function at 18 months compared to tacrolimus.
- Patients treated with tegoprubart reported better health-related quality of life.
💡 Why It Matters
📚 Background
Kidney transplantation is a critical treatment for end-stage renal disease, and advancements in immunosuppressive therapies are vital for improving patient outcomes. Tacrolimus has been the standard treatment, but new therapies like tegoprubart offer hope for better results.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%